Drug Approval | December 28, 2021
Sun Pharma receives DCGI approval for Molxvir in India
The product is expected to be available in a week’s time
The product is expected to be available in a week’s time
DCGI approved the drug based on the review of clinical data
The drug will be marketed under the brand name Molnaflu
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Filing marks first protein-based vaccine submitted to MHRA for authorization
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
Study to explore heterologous regimen of COVID-19 vaccines from different manufacturers in adolescents 12-16 years of age
Subscribe To Our Newsletter & Stay Updated
